- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Myriad Genetics Inc (MYGN)
NASDAQ
Currency in USD
4.45
-0.20(-4.30%)
Closed·
After Hours
4.50+0.05(+1.12%)
·
Fair Value
An estimate of a Myriad Genetics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.45
4.74
52 wk Range
3.81
29.30
MYGN Financial Summary
A brief financial summary of Myriad Genetics Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.
Key Ratios
Statements Highlights
| Period Ending: | 2016 30/06 | 2017 30/06 | 2018 30/06 | 2019 30/06 | 2020 30/06 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 299.8 | 690.6 | 678.4 | 753.2 | 837.6 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 208.4 | 493 | 476.4 | 517 | 585.4 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -87.8 | -126.7 | -123.7 | -138.9 | -88 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -53.1 | -27.2 | -112 | -263.3 | -127.3 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1,418.8 | 1,320.7 | 1,198.7 | 1,146.5 | 1,027.6 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 145.9 | 204.3 | 137.2 | 155.9 | 164.1 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 881 | 967.8 | 885.8 | 783.2 | 701.1 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | - | 149.49 | -115.71 | -61.43 | 13.25 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -73.7 | 18.6 | -106.3 | -110.9 | -8.7 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 28 | 274.4 | -77.5 | 31.9 | -11.9 | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -2.1 | -150.6 | -8 | 152.9 | -7.4 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -46.7 | 141.8 | -192.4 | 74.5 | -29 | |
* In Millions of USD (except for per share items)
Analyst Ratings
3 Buy
9 Hold
3 Sell
Ratings:
15 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 7.46
(+67.68% Upside)
FAQ
What were Myriad Genetics's earnings for the latest quarter?
The Myriad Genetics EPS (TTM) is -1.11. Myriad Genetics reported sales of 195.90, net income of -0.10, and EPS of -0.03 for the latest quarter.
What was Myriad Genetics's net income for the latest quarter?
Myriad Genetics's net income for the latest quarter was -0.10.
How did Myriad Genetics's performance compare year-over-year in the latest quarter?
The company's revenue moved from 210.60 in the previous quarter to 195.90 in the latest quarter, and net income moved from -42.50 to -0.10 compared to the previous quarter.
What is Myriad Genetics's net profit margin on a TTM basis?
Myriad Genetics's trailing twelve months (TTM) net profit margin is -15.20%.
How does Myriad Genetics's debt to equity ratio compare to industry standards?
Myriad Genetics's total debt-to-equity ratio is 22.36%.
What is Myriad Genetics's return on investment on a TTM basis?
Myriad Genetics's trailing twelve months (TTM) return on investment (ROI) is -13.84%.
Did Myriad Genetics gain or lose cash last quarter?
In the latest quarter, Myriad Genetics's net change in cash was -10.90 million.
What were Myriad Genetics's total assets and liabilities in the latest quarter?
As of the latest quarter, Myriad Genetics reported total assets of 1,006.10 million and total liabilities of 151.10 million.
How has Myriad Genetics's total revenue grown this year?
Myriad Genetics's total revenue was 210.60 in the previous quarter and 195.90 in the latest quarter.
What is Myriad Genetics's gross margin on a TTM basis?
Myriad Genetics's trailing twelve months (TTM) gross margin is 70.01%.
What was Myriad Genetics's revenue per share for the latest quarter?
Myriad Genetics's revenue per share for the latest quarter was 31.41.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.